3results about How to "The result is valid" patented technology

This application provides a method and system for correcting the brightness temperature of a spaceborne one-dimensional integrated aperture microwave radiometer. The method includes: acquiring two-dimensional observed brightness temperature data O along the vertical satellite orbit and along the satellite orbit for different ascent and descent orbits of the microwave radiometer; acquiring external data such as atmospheric profiles, surface data, and sea surface salinity along the radiation transmission path to obtain simulated Earth radiation brightness temperature data B, and removing outlier data; subtracting the observed brightness temperature data from the simulated brightness temperature data to obtain O-B data for multiple single orbits, and removing outlier data; taking the median of the O-B data to obtain the average difference in O-B brightness temperature and the two-dimensional corrected brightness temperature; dividing the average difference in O-B brightness temperature by the observed brightness temperatures in the corresponding two vertical directions to obtain two-dimensional relative brightness temperature correction coefficients based on different ascent and descent orbits; and correcting the observed brightness temperature using the two-dimensional relative brightness temperature correction coefficients or the two-dimensional corrected brightness temperature. The advantage of this application is that the established two-dimensional correction coefficients have a better correction effect.

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.